Ameritas Investment Partners’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Ameritas Investment Partners’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-104	Closed	-$2.79K	–	3254
2023 Q1	$2.79K	Hold	104	–	–	﹤0.01%	2936
2022 Q4	$4.41K	Hold	104	–	–	﹤0.01%	2941
2022 Q3	$23K	Buy	104 +35	+51%	+$8.6K	﹤0.01%	2470
2022 Q2	$13K	Hold	69	–	–	﹤0.01%	2768
2022 Q1	$17K	Hold	69	–	–	﹤0.01%	2635
2021 Q4	$11K	Hold	69	–	–	﹤0.01%	2882
2021 Q3	$14K	Hold	69	–	–	﹤0.01%	2855
2021 Q2	$18K	Hold	69	–	–	﹤0.01%	2799
2021 Q1	$18K	Hold	69	–	–	﹤0.01%	2618
2020 Q4	$25K	Hold	69	–	–	﹤0.01%	2364
2020 Q3	$17K	Hold	69	–	–	﹤0.01%	2474
2020 Q2	$20K	Hold	69	–	–	﹤0.01%	2351
2020 Q1	$14K	Hold	69	–	–	﹤0.01%	2383
2019 Q4	$31K	Hold	69	–	–	﹤0.01%	2186
2019 Q3	$21K	Hold	69	–	–	﹤0.01%	2374
2019 Q2	$22K	Buy	+69	New	+$23.9K	﹤0.01%	2401
2017 Q2	–	Sell	-9	Closed	-$3K	–	3063
2017 Q1	$3K	Buy	+9	New	+$3.1K	﹤0.01%	2907

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Ameritas Investment Partners's EIGR Position: Q2 2023 in Review

Ameritas Investment Partners sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2023, closing a stake of 104 shares — an estimated $2.79K sold.

Ameritas Investment Partners first reported a position in EIGR in Q1 2017 and held it in 17 quarters. The position peaked at $31K in Q4 2019. 66 funds tracked by Wall St. Rank hold EIGR as of Q2 2023.

Ameritas Investment Partners reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2023 after selling out during the quarter.
Ameritas Investment Partners sold 104 Eiger BioPharmaceuticals, Inc. shares in Q2 2023, an estimated $2.79K.
Ameritas Investment Partners first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2017 and held it in 17 quarters.
Ameritas Investment Partners's Eiger BioPharmaceuticals, Inc. position peaked at $31K in Q4 2019.
66 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2023.

Based on Ameritas Investment Partners's 13F filing for Q2 2023, filed 11 Aug 2023.